Organization
NSABP Foundation, Inc.
5 abstracts
Abstract
A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008.Org: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, Women and Infants Hospital of Rhode Island,
Abstract
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer.Org: University of Kansas Medical Center Comprehensive Cancer Center (KUMC CCC), Department of Biostatistics, University of Pittsburgh School of Public Health, St. Luke’s University Health Network Cancer Center, Orlando Health Cancer Institute, The Ohio State University Comprehensive Cancer Center,
Abstract
A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009.Org: Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, University of Pittsburgh School of Public Health, University of Pittsburgh Medical Center (UPMC),
Abstract
NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).Org: NRG Oncology Statistical and Data Management Center, Department of Biostatistics at University of Pittsburgh School of Public Health, NSABP Foundation, Inc., UPMC Hillman Cancer Center, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
Abstract
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.Org: University of Texas MD Anderson Cancer Center, The University of Pittsburgh, NRG Oncology SDMC, NSABP Foundation, Inc., UMPC Hillman Cancer Center,